Product Description
an antisense oligonucleotide preventing insulin receptor substrate-1 expression (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24811963/)
Mechanisms of Action: INSR Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gene Signal SAS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Glaucoma, Neovascular|Retinal Vein Occlusion
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STRONG | P3 |
Unknown status |
Retinal Vein Occlusion|Glaucoma, Neovascular |
2019-06-01 |